Crispr Therapeutics AG (CRSP) stock has gained 130.32% over the last 12 months, and the average rating from Wall Street analysts is a Buy. InvestorsObserver’s proprietary ranking system, gives CRSP stock a score of 67 out of a possible 100.
That rank is mainly influenced by a long-term technical score of 96. CRSP's rank also includes a short-term technical score of 94. The fundamental score for CRSP is 11. In addition to the average rating from Wall Street analysts, CRSP stock has a mean target price of 134. This means analysts expect the stock to fall 12.29% over the next 12 months.
What's Happening with CRSP Stock Today
Crispr Therapeutics AG (CRSP) stock has gained 2.94% while the S&P 500 has fallen -0.03% as of 3:17 PM on Monday, Dec 14. CRSP has gained $4.36 from the previous closing price of $148.41 on volume of 1,596,118 shares. Over the past year the S&P 500 is up 14.76% while CRSP has gained 130.32%. CRSP lost -$3.25 per share in the over the last 12 months.